<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543540</url>
  </required_header>
  <id_info>
    <org_study_id>Nexvax2-1005</org_study_id>
    <nct_id>NCT03543540</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease</brief_title>
  <official_title>A Phase 1 Study of Nexvax2 Administered Subcutaneously After a Screening Gluten Food Challenge That Compares Relative Bioavailability With Intradermal Administration in Non-homozygous HLA-DQ2.5+ Adults With Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmusanT, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmusanT, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled clinical study in non-homozygous human
      leukocyte antigen (HLA)-DQ.2.5+ adults with celiac disease (CeD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, randomized,double-blind, placebo-controlled clinical study of Nexvax2, in adult
      subjects with confirmed CeD who, have been following a gluten free diet for at least 12
      consecutive months prior to screening. The study will evaluate the safety and tolerability of
      Nexvax2 administered subcutaneously and will compare the bioavailability of subcutaneous
      versus intradermal administration. The study plan consists of 3 periods: a screening period
      of 3 to 5 weeks, a 46-day treatment period, and a 30-day post-treatment observational
      follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Nexvax 2 administered subcutaneously (SQ)</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Treatment emergent adverse events (TEAEs) will be summarized by treatment group and treatment arm, severity (grades as defined in CTCAE, Version 4.03), relationship to IP, and phase of treatment and presented as the number and percentage of patients reporting an event(s) as well as the number of events reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate bioavailability of the constituents of Nexvax2 after SQ versus intradermal (ID) administration</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Blood draws for plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacodynamics (PD) of the maintenance dose levels of Nexvax2 administered SQ and ID</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Blood draw collected for cytokines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate area under the plasma concentration-time curve for the constituents of Nexvax2 in SQ versus ID maintenance doses.</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Blood draw collected for Pharmacokinetic (PK) sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare elimination half life properties for the constituents of Nexvax2 in SQ versus ID maintenance doses.</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Blood draw collected for PK</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare time to maximal plasma concentration for the constituents of Nexvax2 in SQ versus ID maintenance doses.</measure>
    <time_frame>Treatment Period: 7 weeks</time_frame>
    <description>Blood draw collected for PK</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Celiac Disease</condition>
  <condition>Intestinal Disease</condition>
  <condition>Malabsorption Syndromes</condition>
  <condition>Gastrointestinal Disease</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Metabolic Disease</condition>
  <condition>Coeliac Disease</condition>
  <condition>Gluten Sensitivity</condition>
  <arm_group>
    <arm_group_label>Nexvax2 (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexvax2 (Arm B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexvax2 Placebo (Arm C)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexvax2 Placebo (Arm D)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nexvax2</intervention_name>
    <description>Nexvax2 injections: 14 in total at twice weekly intervals</description>
    <arm_group_label>Nexvax2 (Arm A)</arm_group_label>
    <arm_group_label>Nexvax2 (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injections: 14 in total at twice weekly intervals</description>
    <arm_group_label>Nexvax2 Placebo (Arm C)</arm_group_label>
    <arm_group_label>Nexvax2 Placebo (Arm D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 to 70 years of age (inclusive)

          -  History of medically diagnosed Celiac Disease (CeD) that included duodenal biopsy.

          -  Maintenance of gluten free diet (GFD) for at least 12 consecutive months prior to
             screening.

          -  Willingness to consume a moderate amount of gluten on one occasion during screening.

          -  Able to read and understand English.

        Exclusion Criteria:

          -  History of inflammatory bowel disease and/or microscopic colitis.

          -  Any medical condition or lab abnormality that in the opinion of the investigator may
             interfere with study conduct or would impact the immune response (other than CeD),
             confound interpretation of study results, or pose an increased risk to the subject.

          -  Use of immunomodulatory or immune-suppressing medical treatment during the 6 months
             prior to screening

          -  Use of oral or parenteral immunomodulatory corticosteroids, within the 6 weeks prior
             to screening. Topical or inhaled corticosteroids are acceptable.

          -  Receipt of any investigational drug or participation in another clinical study within
             6 months prior to screening.

          -  Females who are lactating or pregnant

          -  Receipt of any vaccine within 1 week prior to planned first day of the treatment
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Anderson, PhD, FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>ImmusanT, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qpharm Pty Ltd</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.immusant.com/</url>
    <description>ImmusanT</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>September 19, 2018</last_update_submitted>
  <last_update_submitted_qc>September 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

